Lexeo Therapeutics (NASDAQ:LXEO) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Lexeo Therapeutics (NASDAQ:LXEO) issued its quarterly earnings data on Monday. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09, Zacks reports.

Lexeo Therapeutics Price Performance

LXEO stock traded up $1.38 during trading on Monday, hitting $4.09. The company had a trading volume of 6,910,396 shares, compared to its average volume of 328,570. Lexeo Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.50. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $4.19 and a two-hundred day moving average price of $6.76. The company has a market cap of $135.24 million, a P/E ratio of -1.29 and a beta of 3.85.

Analysts Set New Price Targets

A number of research analysts have weighed in on LXEO shares. Leerink Partners cut their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $23.60.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.